Supplement encyclopedia

Bacillus subtilis

Bacillus subtilis is a bacterium that forms hardy spores. Different strains are used in supplements and to make fermented foods such as natto. The codes BS50, MB40, R0179, and CU1 refer to distinct strains that were studied separately.

Double-check the conclusions and review the sources before choosing a supplement.

Main conclusion

Potential benefits

  • In adults with mild bloating, belching, or gas complaints, the combined symptom score fell by at least two points without worsening any individual complaint in about 47 out of 100 people after six weeks of BS50, versus 22 out of 100 with placebo.
  • In the same trial, BS50 showed no convincing advantage for gas alone or for stool frequency and consistency.
  • In adults with frequent or pronounced bloating, MB40 showed no convincing advantage for bloating, abdominal discomfort, or gas over four weeks.
  • In adults with longstanding intestinal complaints, heat-treated BG01-4 reduced the constipation symptom score by 33% from baseline over four weeks, versus 15% with placebo.

[1] [2] [3]

Who was studied

  • In healthy adults with minor baseline complaints, strain R0179 showed no convincing advantage over placebo in general well-being or digestive symptoms over four weeks.
  • In adults aged 60–74 taking CU1 intermittently over 16 weeks, no convincing difference from placebo was found in the number of days with cold-like symptoms or the proportion of people with an episode.
  • With severe illness, weakened immunity, or a central venous catheter, taking live probiotics requires an individual medical assessment because of infection risk.

[1] [2] [3] [4]

Forms studied

  • In the BS50 study, adults took a capsule containing 2 billion CFU daily with their largest meal for six weeks. The MB40 study used 5 billion CFU every morning for four weeks.
  • BG01-4 was studied as heat-treated bacterial powder with maltodextrin: one sachet totaling 1 g daily for four weeks. The contents were added to water, juice, or food.
  • On the package, look for the full strain code, CFU count at the end of shelf life, and storage conditions. CFU denotes the number of viable microorganisms.

[1] [2] [3] [4]

Food sources

  • Food strains of B. subtilis have been isolated from natto, a Japanese food made from fermented soybeans, and from the Korean soybean paste cheonggukjang.
  • They have also been isolated from kinema and thua-nao, foods made from fermented soy.
  • If you take warfarin, consider the vitamin K in natto: before changing the amount in your diet, discuss it with the specialist monitoring your INR.

[1] [2] [3] [4]

Effects and studied questions

How to read the certainty scale 1–4

Certainty is rated separately for each outcome. 1 is very low, 2 is low, 3 is moderate and 4 is high.

Goal or questionResultConfidenceStudiesPopulation studiedKey sources
Combined relief of bloating, belching, and gas — BS50The combined weekly score for bloating, belching, and gas fell by at least 2 points in 47.4% of participants taking BS50 and 22.2% taking placebo (p=0.024). To qualify as a response, none of the three symptoms could worsen by 1 point or more.
2/4 LowOne small six-week study that used subjective symptom ratings. The paper reports 38 participants assigned to each group, but the placebo response percentages are consistent with 36 participants. The paper does not explain why the number of observations differed in this analysis.
11 publication describedThe probiotic Bacillus subtilis BS50 decreases gastrointestinal symptoms in healthy adults: a randomized, double-blind, placebo-controlled trial ↗76 healthy adults aged 30–65 with mild bloating, belching, or gas, with 38 people per group. Everyone completed the study.
  1. The probiotic Bacillus subtilis BS50 decreases gastrointestinal symptoms in healthy adults: a randomized, double-blind, placebo-controlled trial ↗
Gas — BS50Gas decreased by at least 1 point in 47.4% of participants taking BS50 and 44.4% taking placebo. The study found no advantage for BS50 over placebo (p=0.80).
2/4 LowOne small six-week study that used subjective symptom ratings. The paper reports 38 participants assigned to each group, but the placebo response percentages are consistent with 36 participants. The paper does not explain why the number of observations differed in this analysis.
11 publication describedThe probiotic Bacillus subtilis BS50 decreases gastrointestinal symptoms in healthy adults: a randomized, double-blind, placebo-controlled trial ↗76 healthy adults aged 30–65 with mild bloating, belching, or gas, with 38 people per group. Everyone completed the study.
  1. The probiotic Bacillus subtilis BS50 decreases gastrointestinal symptoms in healthy adults: a randomized, double-blind, placebo-controlled trial ↗
Bloating in the full group — MB40Bloating severity on a scale from 0 to 10 fell by 3.06 points with MB40 and 3.03 points with placebo. The difference between groups was not statistically significant.
2/4 LowOne small four-week study. The main reported results cover 91 of the 100 participants assigned to groups. The study assessed several symptoms and considered different degrees of severity.
11 publication describedA Randomized, Double-blind, Placebo-controlled, Parallel Study Evaluating the Efficacy of Bacillus subtilis MB40 to Reduce Abdominal Discomfort, Gas, and Bloating ↗100 adults aged 18–75 with pronounced or frequent bloating and no significant medical conditions. The per-protocol analysis included 91 people, 45 taking MB40 and 46 taking placebo.
  1. A Randomized, Double-blind, Placebo-controlled, Parallel Study Evaluating the Efficacy of Bacillus subtilis MB40 to Reduce Abdominal Discomfort, Gas, and Bloating ↗

The study count refers to the cited source. Reviews with overlapping trials and outcomes from one study are not added together.

Forms

Live strains in capsules BS50, MB40, R0179, and CU1 are distinct strains, each studied separately. On the label, look for the strain code, the CFU count at the end of the shelf life, and the storage instructions. A higher CFU count alone does not mean a greater effect. Heat-treated BG01-4 The study used a sachet containing 1 g of heat-treated powder. The paper also reports 5 billion CFU but does not specify whether that count applies before or after heating. For that reason, it is not listed here as a dose of live bacteria. Food cultures Natto and other fermented foods contain their own food-associated strains. Finding these strains in food does not establish an effect of BS50 or MB40. Preparation can change the number of live bacteria. In one natto study, boiling reduced that number.

Guidance for each goal

Combined relief of bloating, belching, and gas — BS502/4 LowRead moreCollapse
Confidence
2/4 LowOne small six-week study that used subjective symptom ratings. The paper reports 38 participants assigned to each group, but the placebo response percentages are consistent with 36 participants. The paper does not explain why the number of observations differed in this analysis.

Combined relief of the three symptoms was more common.

Study findings. The combined weekly score for bloating, belching, and gas fell by at least 2 points in 47.4% of participants taking BS50 and 22.2% taking placebo (p=0.024). To qualify as a response, none of the three symptoms could worsen by 1 point or more.

Studied regimen2 billion CFU in one capsule daily with the largest mealBS50: spore capsule
Duration and population6 weeks76 healthy adults aged 30–65 with mild bloating, belching, or gas, with 38 people per group. Everyone completed the study.

Comparator: Maltodextrin placebo capsule

Gas — BS502/4 LowRead moreCollapse
Confidence
2/4 LowOne small six-week study that used subjective symptom ratings. The paper reports 38 participants assigned to each group, but the placebo response percentages are consistent with 36 participants. The paper does not explain why the number of observations differed in this analysis.

There was no advantage over placebo for gas alone.

Study findings. Gas decreased by at least 1 point in 47.4% of participants taking BS50 and 44.4% taking placebo. The study found no advantage for BS50 over placebo (p=0.80).

Studied regimen2 billion CFU in one capsule daily with the largest mealBS50: spore capsule
Duration and population6 weeks76 healthy adults aged 30–65 with mild bloating, belching, or gas, with 38 people per group. Everyone completed the study.

Comparator: Maltodextrin placebo capsule

Bloating in the full group — MB402/4 LowRead moreCollapse
Confidence
2/4 LowOne small four-week study. The main reported results cover 91 of the 100 participants assigned to groups. The study assessed several symptoms and considered different degrees of severity.

There was no advantage over placebo for bloating in the full group.

Study findings. Bloating severity on a scale from 0 to 10 fell by 3.06 points with MB40 and 3.03 points with placebo. The difference between groups was not statistically significant.

Studied regimen5 billion CFU in one capsule each morningMB40 (OPTI-BIOME): spore capsule
Duration and population4 weeks after a two-week observation run-in100 adults aged 18–75 with pronounced or frequent bloating and no significant medical conditions. The per-protocol analysis included 91 people, 45 taking MB40 and 46 taking placebo.

Comparator: Capsule with the same inactive ingredients, including maltodextrin, and no probiotic

Abdominal discomfort in the full group — MB402/4 LowRead moreCollapse
Confidence
2/4 LowOne small four-week study. The main reported results cover 91 of the 100 participants assigned to groups. The study assessed several symptoms and considered different degrees of severity.

There was no advantage over placebo for abdominal discomfort in the full group.

Study findings. Abdominal discomfort on a scale from 0 to 10 fell by 2.34 points with MB40 and 2.77 points with placebo. The study found no advantage for MB40 over placebo.

Studied regimen5 billion CFU in one capsule each morningMB40 (OPTI-BIOME): spore capsule
Duration and population4 weeks after a two-week observation run-in100 adults aged 18–75 with pronounced or frequent bloating and no significant medical conditions. The per-protocol analysis included 91 people, 45 taking MB40 and 46 taking placebo.

Comparator: Capsule with the same inactive ingredients, including maltodextrin, and no probiotic

Gas in the full group — MB402/4 LowRead moreCollapse
Confidence
2/4 LowOne small four-week study. The main reported results cover 91 of the 100 participants assigned to groups. The study assessed several symptoms and considered different degrees of severity.

There was no advantage over placebo for gas in the full group.

Study findings. Gas severity on a scale from 0 to 10 fell by 2.24 points with MB40 and 2.12 points with placebo. The difference between groups was not statistically significant.

Studied regimen5 billion CFU in one capsule each morningMB40 (OPTI-BIOME): spore capsule
Duration and population4 weeks after a two-week observation run-in100 adults aged 18–75 with pronounced or frequent bloating and no significant medical conditions. The per-protocol analysis included 91 people, 45 taking MB40 and 46 taking placebo.

Comparator: Capsule with the same inactive ingredients, including maltodextrin, and no probiotic

Bloating in the subgroup of men — MB401/4 Very lowRead moreCollapse
Confidence
1/4 Very lowA very small subgroup of 11 and 10 men. The paper says the analysis by sex was planned. The published trial registration does not independently confirm this. The result for the full group was null. The numerical differences among men did not reach statistical significance, and the study tested several symptoms.

The reduction was numerically larger among men taking MB40, but the difference was not statistically significant.

Study findings. Among men, bloating severity fell by 3.71 points with MB40 and 2.33 points with placebo on a scale from 0 to 10. The numerical difference favored the supplement, but it was not statistically significant.

Studied regimen5 billion CFU in one capsule each morningMB40 (OPTI-BIOME): spore capsule
Duration and population4 weeks after a two-week observation run-inThe subgroup included 21 men who completed the protocol, 11 taking MB40 and 10 taking placebo. The full study included 100 adults aged 18–75 with pronounced or frequent bloating.

Comparator: Capsule with the same inactive ingredients, including maltodextrin, and no probiotic

Days with abdominal discomfort in the subgroup of men — MB401/4 Very lowRead moreCollapse
Confidence
1/4 Very lowA very small subgroup of 11 and 10 men. The paper says the analysis by sex was planned. The published trial registration does not independently confirm this. The result for the full group was null. The numerical differences among men did not reach statistical significance, and the study tested several symptoms.

The reduction was numerically larger among men taking MB40, but the difference was not statistically significant.

Study findings. Among men, the number of days per week with abdominal discomfort fell by 1.82 with MB40 and 0.50 with placebo. The difference in change was 1.32 days. The study found no statistically significant advantage over placebo.

Studied regimen5 billion CFU in one capsule each morningMB40 (OPTI-BIOME): spore capsule
Duration and population4 weeks after a two-week observation run-inThe subgroup included 21 men who completed the protocol, 11 taking MB40 and 10 taking placebo. The full study included 100 adults aged 18–75 with pronounced or frequent bloating.

Comparator: Capsule with the same inactive ingredients, including maltodextrin, and no probiotic

Days with gas in the subgroup of men — MB401/4 Very lowRead moreCollapse
Confidence
1/4 Very lowA very small subgroup of 11 and 10 men. The paper says the analysis by sex was planned. The published trial registration does not independently confirm this. The result for the full group was null. The numerical differences among men did not reach statistical significance, and the study tested several symptoms.

The reduction was numerically larger among men taking MB40, but the difference was not statistically significant.

Study findings. Among men, the number of days per week with gas fell by 1.41 with MB40 and 0.35 with placebo. The difference in change was 1.06 days. The study found no statistically significant advantage over placebo.

Studied regimen5 billion CFU in one capsule each morningMB40 (OPTI-BIOME): spore capsule
Duration and population4 weeks after a two-week observation run-inThe subgroup included 21 men who completed the protocol, 11 taking MB40 and 10 taking placebo. The full study included 100 adults aged 18–75 with pronounced or frequent bloating.

Comparator: Capsule with the same inactive ingredients, including maltodextrin, and no probiotic

General well-being — R01792/4 LowRead moreCollapse
Confidence
2/4 LowThe groups were small, with about 20 people each, and the study primarily assessed tolerability. Symptoms were mild at baseline, limiting the study's ability to detect improvement.

The study found no improvement in well-being.

Study findings. The study found no improvement in general well-being. Average scores for six symptom categories on a daily questionnaire stayed below 1 point on a scale from 0 to 6. Symptoms were mild at baseline.

Studied regimen0.1, 1, or 10 billion CFU in one capsule per day, taken at the end of a mealR0179: capsule containing 75% spores and 25% bacterial cells in their usual growing form
Duration and population4 weeks of use, followed by one additional week of observation after stopping83 healthy adults aged 18–50 were assigned to four groups. A total of 81 completed the study, including 21 at the 0.1 billion CFU dose and 20 each at the 1 billion CFU dose, the 10 billion CFU dose, and placebo.

Comparator: Matching placebo capsule

Digestive symptoms — R01792/4 LowRead moreCollapse
Confidence
2/4 LowThe groups were small, with about 20 people each, and the study primarily assessed tolerability. Symptoms were mild at baseline, limiting the study's ability to detect improvement.

The study found no improvement in digestive symptoms.

Study findings. Digestive symptoms did not improve on the GSRS questionnaire. Average scores for individual symptom categories ranged from 1.1 to 1.9 on a scale from 1 to 7, where 1 means no discomfort.

Studied regimen0.1, 1, or 10 billion CFU in one capsule per day, taken at the end of a mealR0179: capsule containing 75% spores and 25% bacterial cells in their usual growing form
Duration and population4 weeks of use, followed by one additional week of observation after stopping83 healthy adults aged 18–50 were assigned to four groups. A total of 81 completed the study, including 21 at the 0.1 billion CFU dose and 20 each at the 1 billion CFU dose, the 10 billion CFU dose, and placebo.

Comparator: Matching placebo capsule

Bowel movement frequency — BS502/4 LowRead moreCollapse
Confidence
2/4 LowOne small six-week study in which participants kept a bowel movement diary. On average, participants had regular bowel movements and normal stool consistency before the course began. Chronic constipation was not required for participation.

There was no additional increase in bowel movement frequency.

Study findings. Bowel movement frequency did not increase more with BS50 than with placebo. At baseline, the groups averaged 8.6 and 7.9 bowel movements per week, respectively. At week six, they averaged 9.4 and 9.3. The comparison of changes at week six yielded p=0.42.

Studied regimen2 billion CFU in one capsule daily with the largest mealBS50: spore capsule
Duration and population6 weeks76 healthy adults aged 30–65 with mild bloating, belching, or gas, with 38 people per group. Everyone completed the study.

Comparator: Maltodextrin placebo capsule

Stool consistency — BS502/4 LowRead moreCollapse
Confidence
2/4 LowOne small six-week study in which participants kept a bowel movement diary. On average, participants had regular bowel movements and normal stool consistency before the course began. Chronic constipation was not required for participation.

There was no additional change in stool consistency.

Study findings. Stool consistency did not change more with BS50 than with placebo. The mean Bristol Stool Scale score went from 3.9 to 3.8 with BS50 and from 3.6 to 3.7 with placebo. The overall analysis of changes yielded p=0.29.

Studied regimen2 billion CFU in one capsule daily with the largest mealBS50: spore capsule
Duration and population6 weeks76 healthy adults aged 30–65 with mild bloating, belching, or gas, with 38 people per group. Everyone completed the study.

Comparator: Maltodextrin placebo capsule

Constipation symptoms — heat-treated BG01-41/4 Very lowRead moreCollapse
Confidence
1/4 Very lowOne preliminary study in which 13 of the 80 participants assigned to groups did not complete the protocol. The main figure and the table for the additional analysis show different amounts of improvement in constipation. The text also contains errors in group sizes. These discrepancies account for the very low confidence.

The authors reported a preliminary reduction in constipation symptoms.

Study findings. In the main analysis, the authors reported a 33% reduction in constipation symptoms with BG01-4 and a 15% reduction with placebo, as measured by a questionnaire.

Studied regimenOne 1 g sachet per day. Participants added the contents to 250 mL of water, to juice, or to food.BG01-4: heat-treated bacterial powder in a sachet with maltodextrin
Duration and population4 weeksAdults aged 18–75 with self-reported long-standing intestinal complaints. People with irritable bowel syndrome (IBS) were excluded. The study flow diagram shows 80 people assigned to groups (42 and 38) and 67 included in the analysis (34 and 33).

Comparator: Maltodextrin placebo sachet

Days with cold-like symptoms — CU12/4 LowRead moreCollapse
Confidence
2/4 LowOne study of 100 participants over one winter. The study looked at respiratory symptoms in a separate, additional analysis. The primary outcome combined respiratory and intestinal infections.

The study did not confirm a reduction in days with cold-like symptoms.

Study findings. Over 16 weeks, participants reported cold-like symptoms on an average of 4.4 days with CU1 and 6.2 days with placebo. The difference was not statistically significant (p=0.1027).

Studied regimen2 billion spores in one capsule per day, taken 40 minutes before breakfast. Participants took four 10-day courses, each followed by an 18-day break from taking the study capsules.CU1: capsule containing a preparation made up mostly of spores
Duration and population16 weeks of observation, with 40 days of use in total100 independently living adults aged 60–74 with no severe chronic conditions who reported at least two episodes of infection the previous winter, with 50 participants per group. Everyone completed the study.

Comparator: Capsule with the same inactive ingredients and no bacteria, taken on the same schedule

Participants with a cold-like episode — CU12/4 LowRead moreCollapse
Confidence
2/4 LowOne study of 100 participants over one winter. The study looked at respiratory symptoms in a separate, additional analysis. The primary outcome combined respiratory and intestinal infections.

The study did not confirm a reduction in the proportion of participants who had a respiratory episode.

Study findings. At least one respiratory episode occurred in 24 of 50 participants taking CU1 (48%) and 31 of 50 taking placebo (62%). The difference was not statistically significant (p=0.1609).

Studied regimen2 billion spores in one capsule per day, taken 40 minutes before breakfast. Participants took four 10-day courses, each followed by an 18-day break from taking the study capsules.CU1: capsule containing a preparation made up mostly of spores
Duration and population16 weeks of observation, with 40 days of use in total100 independently living adults aged 60–74 with no severe chronic conditions who reported at least two episodes of infection the previous winter, with 50 participants per group. Everyone completed the study.

Comparator: Capsule with the same inactive ingredients and no bacteria, taken on the same schedule

Days with symptoms of respiratory or intestinal infection — CU12/4 LowRead moreCollapse
Confidence
2/4 LowOne study of 100 participants over one winter. This was the primary outcome for the full study population and included both respiratory and intestinal infections.

The study did not confirm a reduction in the total number of days with symptoms of infection.

Study findings. Over 16 weeks, participants averaged 5.1 days with symptoms of respiratory or intestinal infection with CU1 and 6.6 days with placebo. The difference was not statistically significant (p=0.2015).

Studied regimen2 billion spores in one capsule per day, taken 40 minutes before breakfast. Participants took four 10-day courses, each followed by an 18-day break from taking the study capsules.CU1: capsule containing a preparation made up mostly of spores
Duration and population16 weeks of observation, with 40 days of use in total100 independently living adults aged 60–74 with no severe chronic conditions who reported at least two episodes of infection the previous winter, with 50 participants per group. Everyone completed the study.

Comparator: Capsule with the same inactive ingredients and no bacteria, taken on the same schedule

Self-rated sleep quality — BS502/4 LowRead moreCollapse
Confidence
2/4 LowOne small six-week study that assessed sleep by self-report. Most participants were already sleeping well before dosing began. The authors reported a null result without giving final figures for each group.

Self-rated sleep quality did not change.

Study findings. Self-rated sleep quality did not change. At baseline, the average rating was about 7 out of 10, indicating good sleep. The authors did not publish separate figures showing how each group rated its sleep after the course.

Studied regimen2 billion CFU in one capsule daily with the largest mealBS50: spore capsule
Duration and population6 weeks76 healthy adults aged 30–65 with mild bloating, belching, or gas, with 38 people per group. Everyone completed the study.

Comparator: Maltodextrin placebo capsule

Proportion of participants with good or excellent sleep — BS502/4 LowRead moreCollapse
Confidence
2/4 LowOne small six-week study that assessed sleep by self-report. Most participants were already sleeping well before dosing began. The authors reported a null result without giving final figures for each group.

The proportion of people with good or excellent sleep did not change.

Study findings. The proportion of participants who rated their sleep as good or excellent did not change. More than 75% gave these ratings before the course began. The exact proportions for each group after the course were not published.

Studied regimen2 billion CFU in one capsule daily with the largest mealBS50: spore capsule
Duration and population6 weeks76 healthy adults aged 30–65 with mild bloating, belching, or gas, with 38 people per group. Everyone completed the study.

Comparator: Maltodextrin placebo capsule

Safety and limitations

In the study of MB40 at 5 billion CFU per day, adverse events were noted in both groups. Events considered possibly related to the supplement included constipation, abdominal discomfort, diarrhea, gas, and dry mouth. They resolved by the end of the study. In a separate tolerability study of MB40 at 10 billion CFU per day, one participant experienced vomiting and chills, which the authors judged likely related to taking the supplement. The symptoms resolved within 31 hours. In the R0179 study, one participant in the 10 billion CFU group withdrew after experiencing itching and skin redness. A causal link was not established. For people with severe illness, a weakened immune system, or a central venous catheter, using live probiotics requires an individual medical assessment because of the risk of infection. The FDA issued a separate warning for hospitalized premature infants. This information applies to probiotics in general and does not establish the rate of infection from individual B. subtilis strains.

A Randomized, Double-blind, Placebo-controlled, Parallel Study Evaluating the Efficacy of Bacillus subtilis MB40 to Reduce Abdominal Discomfort, Gas, and Bloating ↗ · Evaluation of Bacillus subtilis R0179 on gastrointestinal viability and general wellness: a randomised, double-blind, placebo-controlled trial in healthy adults ↗ · Safety Assessment of Bacillus subtilis MB40 for Use in Foods and Dietary Supplements ↗ · Probiotics — Health Professional Fact Sheet (NIH ODS) ↗ · FDA Raises Concerns About Probiotic Products Sold for Use in Hospitalized Preterm Infants ↗

Interactions

WithEffectActionSource
AntibioticsSome antibiotics may reduce the effects of some probiotics, depending on the drug and the strain.Ask a doctor or pharmacist whether the specific product is compatible with your antibiotic and when to take it.NIH Office of Dietary Supplements: Dietary Supplements for Immune Function and Infectious Diseases — Health Professional Fact Sheet ↗
Warfarin and similar anticoagulants — nattoNatto increases vitamin K intake. A sudden change in dietary vitamin K can affect how warfarin and other vitamin K antagonists work.Agree with the doctor treating you on whether and how to eat natto. Keep your vitamin K intake consistent.NIH Office of Dietary Supplements: Vitamin K — Health Professional Fact Sheet ↗

Food sources

The table lists foods from which B. subtilis was isolated. It does not rank them by bacterial count. These studies did not determine the number of live bacteria in a typical serving. For soy foods, the table gives the form of the sample used in the study. There is no general recommended daily dietary intake or single tolerable upper intake level for B. subtilis. Trial doses apply to specific strains.

Food composition

FoodGroupAmountServingCaloriesSources
Natto — JapanFermented soybeansFermented soy foods—Researchers isolated food strains of B. subtilis from this product.——Whole-Genome Sequencing and Comparative Genome Analysis of Bacillus subtilis Strains Isolated from Non-Salted Fermented Soybean Foods ↗
Kinema — NepalSun-dried blocks of fermented soybeansFermented soy foods—Researchers isolated food strains of B. subtilis from this product.——Whole-Genome Sequencing and Comparative Genome Analysis of Bacillus subtilis Strains Isolated from Non-Salted Fermented Soybean Foods ↗
Cheonggukjang — KoreaFermented soybean pasteFermented soy foods—Researchers isolated food strains of B. subtilis from this product.——Whole-Genome Sequencing and Comparative Genome Analysis of Bacillus subtilis Strains Isolated from Non-Salted Fermented Soybean Foods ↗
Thua nao — ThailandSun-dried soybean sheetsFermented soy foods—Researchers isolated food strains of B. subtilis from this product.——Whole-Genome Sequencing and Comparative Genome Analysis of Bacillus subtilis Strains Isolated from Non-Salted Fermented Soybean Foods ↗
Characterization of Bacillus subtilis strains in Thua nao, a traditional fermented soybean food in northern Thailand ↗
Pepok — MyanmarPartially dried blocks of fermented soybeansFermented soy foods—Researchers isolated food strains of B. subtilis from this product.——Whole-Genome Sequencing and Comparative Genome Analysis of Bacillus subtilis Strains Isolated from Non-Salted Fermented Soybean Foods ↗
Mak thua nao — LaosFermented soybean pasteFermented soy foods—Researchers isolated food strains of B. subtilis from this product.——Whole-Genome Sequencing and Comparative Genome Analysis of Bacillus subtilis Strains Isolated from Non-Salted Fermented Soybean Foods ↗
Soumbala — Burkina FasoCondiment made from fermented seeds of the Parkia biglobosa treeOther fermented legumes—Researchers isolated food strains of B. subtilis from this product.——Genotyping of starter cultures of Bacillus subtilis and Bacillus pumilus for fermentation of African locust bean (Parkia biglobosa) to produce Soumbala ↗
Bikalga — Burkina FasoCondiment made from fermented Hibiscus sabdariffa seedsFermented seeds—Researchers isolated food strains of B. subtilis from this product.——Co-production of surfactin and a novel bacteriocin by Bacillus subtilis subsp. subtilis H4 isolated from Bikalga, an African alkaline Hibiscus sabdariffa seed fermented condiment ↗

Whole-Genome Sequencing and Comparative Genome Analysis of Bacillus subtilis Strains Isolated from Non-Salted Fermented Soybean Foods ↗

Studies

PublicationWhat was studiedParticipantsForm and doseResult
The probiotic Bacillus subtilis BS50 decreases gastrointestinal symptoms in healthy adults: a randomized, double-blind, placebo-controlled trial ↗Combined relief of bloating, belching, and gas — BS50. Gas — BS50. Bowel movement frequency — BS50. Stool consistency — BS50. Self-rated sleep quality — BS50. Proportion of participants with good or excellent sleep — BS50.76 healthy adults aged 30–65 with mild bloating, belching, or gas, with 38 people per group. Everyone completed the study.BS50 spore capsule, 2 billion CFU in one capsule daily with the largest meal for 6 weeks. Comparator: Maltodextrin placebo capsule.Combined relief of the three symptoms was more common. There was no advantage for gas considered on its own. There was no additional increase in bowel movement frequency and no additional change in stool consistency. Self-rated sleep quality and the proportion of people with good or excellent sleep did not change.
A Randomized, Double-blind, Placebo-controlled, Parallel Study Evaluating the Efficacy of Bacillus subtilis MB40 to Reduce Abdominal Discomfort, Gas, and Bloating ↗Bloating in the full group — MB40. Abdominal discomfort in the full group — MB40. Gas in the full group — MB40. Bloating in the subgroup of men — MB40. Days with abdominal discomfort in the subgroup of men — MB40. Days with gas in the subgroup of men — MB40.100 adults aged 18–75 with pronounced or frequent bloating and no significant medical conditions. The per-protocol analysis included 91 people, 45 taking MB40 and 46 taking placebo. The subgroup analysis included 11 and 10 men, respectively.MB40 (OPTI-BIOME) spore capsule, 5 billion CFU in one capsule each morning for 4 weeks after a two-week observation run-in. Comparator: Capsule with the same inactive ingredients, including maltodextrin, and no probiotic.In the full group, MB40 showed no advantage over placebo for bloating, abdominal discomfort, or gas. Among men, changes in these outcomes were numerically larger with MB40, but the differences from placebo were not statistically significant.

Sources

Sources
  1. The probiotic Bacillus subtilis BS50 decreases gastrointestinal symptoms in healthy adults: a randomized, double-blind, placebo-controlled trial ↗
  2. A Randomized, Double-blind, Placebo-controlled, Parallel Study Evaluating the Efficacy of Bacillus subtilis MB40 to Reduce Abdominal Discomfort, Gas, and Bloating ↗
  3. Evaluation of Bacillus subtilis R0179 on gastrointestinal viability and general wellness: a randomised, double-blind, placebo-controlled trial in healthy adults ↗
  4. Bacillus Subtilis (BG01-4(TM)) Improves Self-Reported Symptoms for Constipation, Indigestion, and Dyspepsia: A Phase 1/2A Randomized Controlled Trial ↗
  5. Probiotic strain Bacillus subtilis CU1 stimulates immune system of elderly during common infectious disease period: a randomized, double-blind placebo-controlled study ↗
  6. Probiotics — Health Professional Fact Sheet (NIH ODS) ↗
  7. Whole-Genome Sequencing and Comparative Genome Analysis of Bacillus subtilis Strains Isolated from Non-Salted Fermented Soybean Foods ↗
  8. Characterization of Bacillus subtilis strains in Thua nao, a traditional fermented soybean food in northern Thailand ↗
  9. Genotyping of starter cultures of Bacillus subtilis and Bacillus pumilus for fermentation of African locust bean (Parkia biglobosa) to produce Soumbala ↗
  10. Co-production of surfactin and a novel bacteriocin by Bacillus subtilis subsp. subtilis H4 isolated from Bikalga, an African alkaline Hibiscus sabdariffa seed fermented condiment ↗
  11. Safety Assessment of Bacillus subtilis MB40 for Use in Foods and Dietary Supplements ↗
  12. FDA Raises Concerns About Probiotic Products Sold for Use in Hospitalized Preterm Infants ↗
  13. Treatment of natto, a fermented soybean preparation, to prevent excessive plasma vitamin K concentrations in patients taking warfarin ↗
  14. NIH Office of Dietary Supplements: Dietary Supplements for Immune Function and Infectious Diseases — Health Professional Fact Sheet ↗
  15. NIH Office of Dietary Supplements: Vitamin K — Health Professional Fact Sheet ↗